Racura taps Purdue expertise to decode MYC-silencing mechanism of (E,E)-bisantrene

Race Oncology Ltd. ( (AU:RAC) ) has issued an announcement.

Racura Oncology has entered a research collaboration with Purdue University to investigate how its lead compound (E,E)-bisantrene binds to G-quadruplex DNA structures in the MYC gene promoter to silence MYC transcription in cancer cells. The program, led by G4 structural biology expert Professor Danzhou Yang, will use high-resolution NMR, X-ray and complementary techniques to define the molecular basis of MYC-G4 binding and its impact on regulatory proteins and gene expression.

Early Purdue data indicate that (E,E)-bisantrene directly engages the MYC G-quadruplex to form a stable 2:1 drug–DNA complex, supporting Racura’s strategy of targeting MYC via promoter DNA rather than the historically intractable MYC protein. Over the next two years, the partners aim to generate peer-reviewed, high-impact mechanism-of-action data that can be shared with prospective pharmaceutical partners, potentially strengthening Racura’s scientific credibility and deal-making position in MYC-focused oncology.

The most recent analyst rating on (AU:RAC) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.

More about Race Oncology Ltd.

Racura Oncology Ltd is an Australian clinical-stage biotechnology company focused on developing targeted cancer therapies. Its lead asset, the anthracene-based compound (E,E)-bisantrene, is being advanced as a precision oncology drug with a particular emphasis on MYC-driven cancers, a segment that represents a large unmet medical need across multiple tumour types.

Average Trading Volume: 181,275

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$465.4M

For an in-depth examination of RAC stock, go to TipRanks’ Overview page.